X

Drug Profile

GS 6679

Alternative Names: GS-6679; HBV Therapy- Gilead Sciences/Hookipa Pharma; Hookipa HBV vaccine

Latest Information Update: 28 Oct 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hookipa Pharma
Developer Gilead Sciences; Hookipa Pharma
Class Hepatitis B vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Hepatitis B

Most Recent Events

28 Oct 2023 No recent reports of development identified for preclinical development in Hepatitis-B in Austria
28 Oct 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA
16 May 2022 Hookipa Pharma announces intention to file IND application for Hepatitis B in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com